Fc gamma receptor polymorphisms and KRAS status as predictive biomarkers in patients with metastatic colorectal cancer treated with biweekly cetuximab-based salvage therapy.

Ruth Zarate,Eva Bandrés,J Rodriguez,Nerea Bitarte,Beatriz Honorato,Valentina Boni,Iosu Sola,Mariano Ponz-Sarvise,Carlos Garzon,J. Garcia-Foncillas

Fc gamma receptor polymorphisms and KRAS status as predictive biomarkers in patients with metastatic colorectal cancer treated with biweekly cetuximab-based salvage therapy.

2010

Ruth Zarate
Eva Bandrés
J Rodriguez
Nerea Bitarte
Beatriz Honorato
Valentina Boni
Iosu Sola
Mariano Ponz-Sarvise
Carlos Garzon
J. Garcia-Foncillas

e13523 Background: Cetuximab has shown a clinically significant antitumor activity against metastatic colorectal cancer (mCRC) both in first and subsequent lines of therapy. Biweekly schedules have...

Keywords:

Cetuximab
Fc-Gamma Receptor
Colorectal cancer
KRAS
Salvage therapy
Biomarker (medicine)
Oncology
Internal medicine
Medicine
predictive biomarker
in patient
antitumor activity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations